Filing Flows

Filing Flows › Health Care › 60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals (SXTP) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · 60 Degrees Pharmaceuticals (SXTP) Q2 2026 earnings results →

Q2 2026 Revenue up 106% year over year to $208K

60 Degrees Pharmaceuticals made $208K in Q2 2026 (+106% Y/Y). Operating margin n/m, net loss $2.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.

Revenue$208K
Year over year+106%
Operating marginn/m
Net earnings−$2.3M
Operating cash flow−$2.2M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $208K in Q2 2026, up 106% year over year and up 28% from the previous quarter.

Gross margin was 27.3%, down 23.1 points from Q2 2025. Operating costs exceeded revenue by $2.3M, an operating margin of -1092.4%. Operating expenses grew 40% against revenue growth of 106%. The quarter ended with a net loss of $2.3M, wider than the previous quarter's $2.1M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $2.3M.

Operating cash flow was −$2.2M. Non-cash charges added back $31K of depreciation and amortization and $98K of share-based compensation.

Quarterly history

60 Degrees Pharmaceuticals revenue by quarter60 Degrees Pharmaceuticals revenue by quarter$242KQ4 2024$164KQ1 2025$101KQ2 2025$438KQ3 2025$303KQ4 2025$162KQ1 2026$208KQ2 2026
60 Degrees Pharmaceuticals net earnings by quarter60 Degrees Pharmaceuticals net earnings by quarter−$2.0MQ4 2024−$1.9MQ1 2025−$1.7MQ2 2025−$2.3MQ3 2025−$1.4MQ4 2025−$2.1MQ1 2026−$2.3MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 14, 2026$208K+106%n/m−$2.3M−$2.2M
Q1 202610-QMay 15, 2026$162K-0.9%n/m−$2.1M−$2.7M
Q4 202510-KMar 30, 2026$303K+26%-632.0%−$1.4M−$1.7M
Q3 202510-QNov 13, 2025$438K+223%-531.4%−$2.3M−$2.1M
Q2 202510-QAug 13, 2025$101K-19%n/m−$1.7M−$1.5M
Q1 202510-QMay 15, 2025$164K+55%n/m−$1.9M−$1.6M
Q4 202410-KMar 27, 2025$242K+92%-854.7%−$2.0M−$1.6M

Charts

60 Degrees Pharmaceuticals: revenue growth, year over year and quarter over quarter60 Degrees Pharmaceuticals: revenue growth, year over year and quarter over quarterY/YQ/Q+92%Q4 2024+55%-32%Q1 2025-19%-38%Q2 2025+223%+334%Q3 2025+26%-31%Q4 2025-1%-47%Q1 2026+106%+28%Q2 2026
Latest (Q2 2026): Y/Y +106%, Q/Q +28%.
60 Degrees Pharmaceuticals: where the cash came from (+) and went (−), TTM to Q2 202660 Degrees Pharmaceuticals: where the cash came from (+) and went (−), TTM to Q2 2026Operating cash flow−$8.8MOther financing$8.1MCash drawn (+) / kept (−)$944KOther investing−$168KCapital spending−$120KExchange rates$8K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
60 Degrees Pharmaceuticals: profit against cash, quarter by quarter60 Degrees Pharmaceuticals: profit against cash, quarter by quarterNet incomeOperating cash flow−$2.2M−$1.7MQ3 2024−$2.0M−$1.6MQ4 2024−$1.9M−$1.6MQ1 2025−$1.7M−$1.5MQ2 2025−$2.3M−$2.1MQ3 2025−$1.4M−$1.7MQ4 2025−$2.1M−$2.7MQ1 2026−$2.3M−$2.2MQ2 2026
Latest (Q2 2026): Net income −$2.3M, Operating cash flow −$2.2M.
60 Degrees Pharmaceuticals: diluted shares by fiscal year (split-adjusted)60 Degrees Pharmaceuticals: diluted shares by fiscal year (split-adjusted)12MFY20220MFY20231MFY20241MFY2025
-94.3% since FY2022: buybacks shrank the count; earlier years scaled for the 5-for-1 split before FY2025.
60 Degrees Pharmaceuticals: long-term debt falling due (FY2025)60 Degrees Pharmaceuticals: long-term debt falling due (FY2025)$1K2026$3K2027$3K2028$3K2029$4K2030$136KLater
Cash $1.5M, short-term investments $1.2M, long-term debt $150K at 2025-12-31.
60 Degrees Pharmaceuticals in its industry: growth against margin (225 companies, SIC 2834)60 Degrees Pharmaceuticals in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMSXTP (+106%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9 , 2010 (“ 60 P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the “Company”, “ 60 P”, or “ 60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60 P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018 .

In its own words, from its 10-Q, filed Aug 14, 2026.

60 Degrees Pharmaceuticals against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +106% against the peers' median +10%.

CompanyQuarterRevenueY/YOp. margin
SXTP 60 Degrees PharmaceuticalsQ2 2026$208K+106%n/m
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: 60 Degrees Pharmaceuticals 10-Q on SEC EDGAR · CIK 1946563 · Pharmaceutical Preparations

13F: who owns SXTP and who is buying

Largest holders of SXTP (13F)Largest holders of SXTP (13F)Kathmere Capital Management, LLC$467KCitadel Advisors LLC$39KXTX Topco$31KKovack Advisors$26KGeode Capital Management, LLC$26KUBS Group AG$24KBarclays$2KOsaic Holdings$44
Funds' net buying of SXTP by quarter (13F)Funds' net buying of SXTP by quarter (13F)$340K2026-03$273K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on SXTP

History

Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare SXTP with

中文版：60 Degrees Pharmaceuticals（SXTP）财报

Español · Français